Quidel to Present at Raymond James 43rd Annual Institutional Investors Conference
February 28 2022 - 6:30PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a leading provider of
rapid diagnostic testing solutions, cellular-based virology assays
and molecular diagnostic systems, announced today that it will
present at the Raymond James & Associates 43rd Annual
Institutional Investors Conference to be held at the J.W. Marriott
Orlando Grande Lakes hotel in Orlando, Florida on Wednesday, March
9, 2022 at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time).
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on March 9th with a
question-and-answer session scheduled immediately following the
presentation. During the presentation, the company will discuss
business and financial developments and trends. The company's
statements may contain or constitute material information that has
not been previously disclosed.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company’s
website at http://ir.quidel.com or by clicking the link below.
https://kvgo.com/rj-43rd-iic/quidel-corp-march-2022
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first FDA-cleared
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s
comprehensive product portfolio includes tests for a wide range of
infectious diseases, cardiac and autoimmune biomarkers, as well as
a host of products to detect COVID-19. With products made in
America, Quidel’s mission is to provide patients with immediate and
frequent access to highly accurate, affordable testing for the good
of our families, our communities and the world. For more
information about Quidel, visit quidel.com.
View our story told by our people at www.quidel.com/ourstory
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228006135/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024